Epigenetic Control of CDK5 Promoter Regulates Diabetes-Associated Development of Alzheimer's Disease

被引:8
|
作者
Cai, Hong-Bin [1 ]
Fan, Zhen-Zhen [1 ]
Tian, Ting [1 ]
Zhao, Chon-Chon [1 ]
Ge, Zhao-Ming [1 ]
机构
[1] Lanzhou Univ, Dept Neurol, Hosp 2, 82 Cuiyingmen, Lanzhou 730000, Gansu, Peoples R China
关键词
Alzheimer's disease; cyclin-dependent kinase-5; diabetes; methylation; promoter acetylation; tau; AMYLOID-BETA; P35; PATHOGENESIS; DYSFUNCTION; AUTOPHAGY; ACTIVATOR;
D O I
10.3233/JAD-190227
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cyclin-dependent kinase-5 (CDK5) is activated by p35 and then binds to both p35 and its truncated form p25 to promote hyperphosphorylation of tau protein, thereby facilitating the pathological progression of Alzheimer's disease (AD). However, it is unknown whether a patient's diabetic status promotes the later onset of AD in a CDK5-dependent manner. Here, we induced pro-diabetic insulin resistance and glucose intolerance in rats using a combined high fat and high glucose diet. Compared to normal diet-fed rats, these pro-diabetic rats exhibited poorer behavioral performance in the Morris water maze test and the novel object recognition test. Increased phosphorylation of tau protein was detected in the hippocampal CAl region of the rat brain, suggesting neurodegeneration. Moreover, CDK5 transcriptional activity was significantly increased in the HFGD-rat brain, likely resulting from an increase in acetylation and a decrease in methylation of the CDK5 promoter. Together, these data suggest that epigenetic control of the CDK5 promoter by acetylation and methylation may regulate the diabetes-associated development of AD.
引用
收藏
页码:743 / 750
页数:8
相关论文
共 50 条
  • [1] The Role of Cdk5 in Alzheimer's Disease
    Liu, Shu-Lei
    Wang, Chong
    Jiang, Teng
    Tan, Lan
    Xing, Ang
    Yu, Jin-Tai
    MOLECULAR NEUROBIOLOGY, 2016, 53 (07) : 4328 - 4342
  • [2] The Role of Cdk5 in Alzheimer’s Disease
    Shu-Lei Liu
    Chong Wang
    Teng Jiang
    Lan Tan
    Ang Xing
    Jin-Tai Yu
    Molecular Neurobiology, 2016, 53 : 4328 - 4342
  • [3] CDK5: The Connection Between Alzheimer's Disease and Type 2 Diabetes?
    Mora, Kevin Edgar
    Aguanno, Ann
    FASEB JOURNAL, 2018, 32 (01):
  • [4] Role of cdk5 in the pathogenesis of Alzheimer's disease
    Lau, LF
    Ahlijanian, MK
    NEUROSIGNALS, 2003, 12 (4-5) : 209 - 214
  • [5] Cdk5 deregulation in the pathogenesis of Alzheimer's disease
    Cruz, JC
    Tsai, LH
    TRENDS IN MOLECULAR MEDICINE, 2004, 10 (09) : 452 - 458
  • [6] Cdk5, a therapeutic target for Alzheimer's disease?
    Tsai, LH
    Lee, MS
    Cruz, J
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2004, 1697 (1-2): : 137 - 142
  • [7] Investigating the Role of Cdk5 in Alzheimer's Disease and Type-2 Diabetes
    Furnari, Julia Lynn
    Aguanno, Ann
    FASEB JOURNAL, 2019, 33
  • [8] Silencing of CDK5 as potential therapy for Alzheimer's disease
    Lopez-Tobon, Alejandro
    Fredy Castro-Alvarez, John
    Piedrahita, Diego
    Boudreau, Ryan L.
    Carlos Gallego-Gomez, Juan
    Patricia Cardona-Gomez, Gloria
    REVIEWS IN THE NEUROSCIENCES, 2011, 22 (02) : 143 - 152
  • [9] Cdk5 as a drug target for the treatment of Alzheimer’s disease
    Lit-Fui Lau
    Patricia A. Seymour
    Mark A. Sanner
    Joel B. Schachter
    Journal of Molecular Neuroscience, 2002, 19 : 267 - 273
  • [10] Cdk5 as a drug target for the treatment of Alzheimer's disease
    Lau, LF
    Seymour, PA
    Sanner, MA
    Schachter, JB
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 19 (03) : 267 - 273